|
Lucinda Osborne is a partner based in our London office. A UK-qualified solicitor with 20 years experience, Ms. Osborne is a member of the firm’s corporate and intellectual property practice groups and concentrates on transactional matters for pharmaceutical and biotech clients. She regularly advises clients in connection with their in and out-licensing activities, joint ventures, and collaborations and other strategic transactions, as well as the full range of commercial agreements that span the product life-cycle in the life sciences sector. Her expertise includes clinical trial agreements, evaluation agreements, manufacturing and supply arrangements, distribution and other marketing agreements, and tenders. She has particular experience structuring and documenting global collaborations to reflect market practices and requirements in the United States.
Representative Matters
- Represented AstraZeneca in an agreement with Moderna Therapeutics to develop and commercialize pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic, and renal diseases, as well as cancer, which involved an upfront payment of $240 million and up to an additional $180 million in technical milestones.
- Advised Vernalis plc in connection with a license agreement with Tris Pharma, Inc to develop up to six novel formulations of existing products sold in the US prescription cough/cold market.
- Continues to advise UCB on commercial and strategic transactions with past representations including its strategic partnership with Wilex AG pursuant to which Wilex acquired world-wide rights to develop UCB's preclinical oncology portfolio, comprising two small-molecule programmes and three antibody programmes, and UCB retained exclusive rights to re-purchase each of those five programmes, following completion of initial clinical feasibility studies for each programme.
- Represented Emergent BioSolutions, on a variety of strategic transactions in Europe including the creation of its joint venture and related licensing and commercial arrangements with the University of Oxford and its technology transfer office, Isis Innovation Limited, to further develop MVA85A, thought to be the world’s most clinically advanced vaccine candidate for the prevention of tuberculosis.
- Advised Boehringer Ingelheim Vetmedica Inc. in its acquisition of certain animal health products divested by Wyeth and Pfizer Inc. pursuant to an FTC consent order entered into in connection with Pfizer Inc.’s acquisition of Wyeth.
- Represented Intercell AG in connection with its acquisition of Cytos Biotechnology Ltd’s platform technology for monoclonal antibody discovery.
- Represented Amyris, Inc. which operates an industrial synthetic biology platform, in a partnership with Total, an international oil and gas company, to develop products under a wide-spectrum master development and collaboration agreement.
Honors and Rankings
- Super Lawyers - London, Business Affairs (2013)
- PLC’s Life Sciences, Which Lawyer?, Commercial & Partnering (2006-2012)
- IAM Patent 1000 - The World’s Leading Patent Practitioners (2012-2013)
- Legal 500 UK, Pharmaceuticals and Biotechnology (2010-2012)
Publications and Speeches
- "Negotiation of Life Sciences Collaboration and Licence Agreements," Negotiating, Understanding and Drafting Commercial Contracts for the Pharmaceutical Industry Seminar (11/14/2011)
- "Early Licensing and R&D," Pharmaceutical Law Summer School, London (7/18/2008)
- "Joint Research and Development Arrangements," Transactions in the Life Sciences Sector (4/24/2007)
|
|